Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Signaling Lymphocyte Activation Molecule Family Member 7 (SLAMF7)
- Target
- SLAMF7
- Molecular classification
- Type I transmembrane glycoprotein, Receptor, Immunoglobulin superfamily
01
Overview
Signaling Lymphocyte Activation Molecule Family Member 7 (SLAMF7) is a type I transmembrane protein highly expressed on NK cells and plasma cells, as well as subsets of T cells, B cells, monocytes/macrophages, and dendritic cells. It functions as a self-ligand receptor mediating cell-cell interactions within the immune system. SLAMF7 promotes NK cell cytotoxicity and modulates inflammatory responses. It is a therapeutic target in multiple myeloma and other CD319-positive malignancies and is targeted by monoclonal antibodies and CAR-T therapies. Upregulation of expression occurs via TLR/NF-kB signaling. It is also implicated in negative regulation of survival/proliferation for innate-like CD8+ and NKT cells.
- Other names
- CD319CS1CRACC
02
Mechanism of action
Antibody-dependent cellular cytotoxicity (ADCC); direct signaling through SLAMF7
03
Biological functions
Immune responseCell-cell interactionCytotoxicity enhancementImmune modulationInflammation controlSignal transduction
04
Disease associations
Multiple MyelomaInflammationSepsisCancer
05
Safety considerations
Immune-related adverse eventsCytokine release syndrome (CRS) in CAR-T therapy
06
Interacting drugs
Elotuzumab
07
Biomarkers
SLAMF7 expression level in plasma cells/tumor cells
Beyond the preview
Go deeper on Signaling Lymphocyte Activation Molecule Family Member 7 (SLAMF7).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Signaling Lymphocyte Activation Molecule Family Member 7 (SLAMF7).